Literature DB >> 8649785

A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome.

J M Varley1, G McGown, M Thorncroft, S Cochrane, P Morrison, P Woll, A M Kelsey, E L Mitchell, J Boyle, J M Birch, D G Evans.   

Abstract

We report details of a family with classic Li-Fraumeni syndrome in which there is a mutation in codon 344 of the tumour suppressor gene TP53. Codon 344 is a key residue within the tetramerisation domain, and the amino acid substitution of a proline for a leucine is predicted to have profound implications for tetramerisation and potentially DNA binding. This is the first report of a mutation at this residue in either sporadic tumours or in the germline and the first report of a germline mutation within the tetramerisation domain. The family does not appear to be remarkable in the spectrum of tumours, and there is loss of the wild-type allele in a leiomyosarcoma from the proband. A cell line has been established from the tumour of the proband and cytogenetic and molecular studies carried out, providing an extensive analysis in this family.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649785

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking.

Authors:  J M Stommel; N D Marchenko; G S Jimenez; U M Moll; T J Hope; G M Wahl
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

2.  In vitro evolution of thermostable p53 variants.

Authors:  I Matsumura; A D Ellington
Journal:  Protein Sci       Date:  1999-04       Impact factor: 6.725

Review 3.  Familial pediatric endocrine tumors.

Authors:  Sarinda Millar; Lisa Bradley; Deirdre E Donnelly; Dennis Carson; Patrick J Morrison
Journal:  Oncologist       Date:  2011-09-20

Review 4.  Genotype phenotype correlation in Li-Fraumeni syndrome kindreds and its implications for management.

Authors:  R N Moule; S G Jhavar; R A Eeles
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

5.  Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center.

Authors:  Montserrat Ayala-Ramirez; Sina Jasim; Lei Feng; Shamim Ejaz; Ferhat Deniz; Naifa Busaidy; Steven G Waguespack; Aung Naing; Kanishka Sircar; Christopher G Wood; Lance Pagliaro; Camilo Jimenez; Rena Vassilopoulou-Sellin; Mouhammed Amir Habra
Journal:  Eur J Endocrinol       Date:  2013-10-23       Impact factor: 6.664

6.  Further evidence for pathogenicity of the TP53 tetramerization domain mutation p.Arg342Pro in Li-Fraumeni syndrome.

Authors:  Anna Etzold; Julia C Schröder; Oliver Bartsch; Ulrich Zechner; Danuta Galetzka
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

7.  Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53.

Authors:  Sridharan Rajagopalan; Fang Huang; Alan R Fersht
Journal:  Nucleic Acids Res       Date:  2010-11-18       Impact factor: 16.971

8.  P53 germline mutations in childhood cancers and cancer risk for carrier individuals.

Authors:  A Chompret; L Brugières; M Ronsin; M Gardes; F Dessarps-Freichey; A Abel; D Hua; L Ligot; M G Dondon; B Bressac-de Paillerets; T Frébourg; J Lemerle; C Bonaïti-Pellié; J Feunteun
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

9.  p53 Oligomerization is essential for its C-terminal lysine acetylation.

Authors:  Yoko Itahana; Hengming Ke; Yanping Zhang
Journal:  J Biol Chem       Date:  2008-12-23       Impact factor: 5.157

10.  Chromosome instability is a predominant trait of fibroblasts from Li-Fraumeni families.

Authors:  J M Boyle; E L Mitchell; M J Greaves; S A Roberts; K Tricker; E Burt; J M Varley; J M Birch; D Scott
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.